Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | FPR3 | P25089 | 3/20 | 0.32 |
| ▸ | FPR2 | P25090 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24607256 | 0.86 | CYP2D6 (0.36) | CYP2D6CYP1A2ALOX15ROCK2ROCK1 | |
| SCHEMBL22856088 | 0.84 | CYP2D6 (0.53) | CYP2D6CYP1A2SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL25568027 | 0.83 | ROCK2 (0.37) | ROCK2ROCK1FPR3FPR2 | |
| SCHEMBL25480049 | 0.82 | CYP2D6 (0.36) | CYP2D6CYP1A2ALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL23135139 | 0.79 | CYP2D6 (0.41) | CYP2D6CYP1A2ALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL22477421 | 0.79 | CYP2D6 (0.41) | CYP2D6CYP1A2ALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL23135133 | 0.78 | CYP2D6 (0.40) | CYP2D6CYP1A2SMN1; SMN2CYP3A4 | |
| SCHEMBL22477390 | 0.76 | ALOX15 (0.42) | CYP2D6CYP1A2ALOX15SMN1; SMN2 | |
| SCHEMBL22477401 | 0.76 | CYP2D6 (0.41) | CYP2D6CYP1A2ALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL24784256 | 0.75 | ROCK2 (0.39) | CYP1A2ROCK2ROCK1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885CYP1A2 3570/4885ALOX15 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.